http://pubs.acs.org/doi/pdf/10.1021/cr400460s

Metallodrugs in Medicinal Inorganic Chemistry

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide. Discovered 30 years ago, it is produced as a consequence of alternative RNA processing of the calcitonin gene. CGRP has two major forms (α and β). It belongs to a group of peptides that all act on an unusual receptor family. These receptors consist of calcitonin receptor-like receptor (CLR) linked to an essential receptor activity modifying protein (RAMP) that is necessary for full functionality. CGRP is a highly potent vasodilator and, partly as a consequence, possesses protective mechanisms that are important for physiological and pathological conditions involving the cardiovascular system and wound healing. CGRP is primarily released from sensory nerves and thus is implicated in pain pathways. The proven ability of CGRP antagonists to alleviate migraine has been of most interest in terms of drug development, and knowledge to date concerning this potential therapeutic area is discussed. Other areas covered, where there is less information known on CGRP, include arthritis, skin conditions, diabetes, and obesity. It is concluded that CGRP is an important peptide in mammalian biology, but it is too early at present to know if new medicines for disease treatment will emerge from our knowledge concerning this molecule.

Calcitonin Gene-Related Peptide: Physiology and Pathophysiology

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of the first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. Ruthenium(iii) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(ii) complexes have also attracted significant attention as anticancer candidates; however, only a few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(ii) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(ii)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(ii) complexes, their targeted delivery, and their activity in nanomaterial systems.

/pdf/the-development-of-anticancer-ruthenium-ii-complexes-from-35e09q82ra.pdf

The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials

http://www.its.caltech.edu/~jkbgrp/abstracts/A267.pdf

Metallo-intercalators and metallo-insertors

Metal complexes of sulphur-nitrogen chelating agents

Biological Activity of Complex Ions

Sexadentate Chelate Compounds. VIII1

Sexadentate Chelate Compounds. XI

The Resolution of a Bis-Tridentate Iron(II) Complex

IN an earlier communication1, a number of experiments were described leading to the conclusion that the activities of enantiomeric ions could be changed to a different extent by the addition of an electrolyte containing an optically active anion or cation. In order to demonstrate the general applicability of this principle, we have sought to resolve a typical non-electrolytic complex salt without salt-forming groups. The peripheral atoms in the tris-acetylacetone cobalt III complex probably carry a slight negative charge, and hence negative or anionic asymmetrical fields are associated with the antipodal forms. The maximum differential interaction in solution is to be expected with a multiply-charged optically active cation, and for the purpose d- and l-tris-ethylene-diamine cobalt III iodides were used.

E. C. Gyarfas

Papers

Biological Activity of Complex Ions

Sexadentate Chelate Compounds. VIII1

Sexadentate Chelate Compounds. XI

The Resolution of a Bis-Tridentate Iron(II) Complex

Preparation of the optical forms of tris-acetylacetone cobalt III.